8-K: Enhabit Reports Mixed Q3 Results with Hospice Growth Offsetting Home Health Decline

Enhabit's third quarter results show a net loss of $110.2 million, but adjusted EBITDA grew by 5.6% year-over-year, driven by hospice revenue and cost reductions.

Summary

• Enhabit reported a net loss of $110.2 million for the third quarter of 2024, which translates to a loss per share of $2.20.
• However, the company's adjusted EBITDA increased by 5.6% year-over-year to $24.5 million, primarily due to home office expense reductions and revenue growth in the hospice segment.
• Consolidated revenue decreased by 1.8% year-over-year to $253.6 million, mainly due to lower Medicare volume in the home health segment.
• Non-Medicare admissions in home health increased by 20.1%, contributing to a total admissions growth of 5.6% year-over-year.
• Hospice average daily census increased by 6.9% year-over-year, with admissions up by 5.7%.
• The company reduced its bank debt by $10 million during the quarter.
• Enhabit has revised its full-year 2024 guidance, with net service revenue expected to be between $1,031 and $1,046 million, adjusted EBITDA between $98 and $102 million, and adjusted EPS between $0.19 and $0.29.

Sentiment

Score: 4

Explanation: The document presents mixed results with positive adjusted EBITDA growth offset by a significant net loss and downward guidance revision. The sentiment is cautiously negative due to the challenges in the home health segment and the overall financial performance.

Positives

• Adjusted EBITDA showed a year-over-year increase, indicating improved profitability.
• Strong growth in non-Medicare admissions and hospice average daily census suggests successful strategic initiatives.
• Debt reduction of $10 million demonstrates improved financial management.
• Improved rates in payor innovation contracts are contributing to revenue growth.
• Home health readmission rates are significantly better than the national average.
• Hospice patient care metrics are significantly better than the national average.

Negatives

• The company reported a significant net loss of $110.2 million for the quarter.
• Consolidated revenue decreased by 1.8% year-over-year, primarily due to lower Medicare volume in home health.
• Home health revenue declined by 4.7% year-over-year.
• Adjusted EBITDA in the home health segment decreased by 12.7% year-over-year.
• Medicare admissions and recertifications in home health decreased by 8.5% and 16.7% respectively.
• The company has revised its full-year 2024 guidance downwards.

Risks

• Lower Medicare volume and recertifications in the home health segment are negatively impacting revenue.
• The company faces challenges in controlling costs, particularly in the home health segment where cost per visit increased by 1.1% year-over-year.
• The revised full-year 2024 guidance indicates potential challenges in meeting previous financial targets.
• The company accrued $1.4 million in Medicare Cap billing limitations compared to $20 thousand in the third quarter of 2023.
• Hurricanes in September and October impacted the company's operations and financial results.

Future Outlook

The company has revised its full-year 2024 guidance, with net service revenue expected to be between $1,031 and $1,046 million, adjusted EBITDA between $98 and $102 million, and adjusted EPS between $0.19 and $0.29. These revisions are based on the impact of lower recertifications in the third quarter and the impact from hurricanes in September and October.

Management Comments

• Our continued progress in our strategies during the third quarter resulted in Adjusted EBITDA growth year over year and strong free cash flow generation that led to further debt reduction, said Enhabits President and Chief Executive Officer Barb Jacobsmeyer.
• The payor innovation strategy continues to foster Medicare Advantage growth in our home health segment, and average daily census continues to grow in our hospice segment.

Industry Context

The home health and hospice care industry is facing challenges related to reimbursement rates and regulatory changes. Enhabit's focus on payor innovation and cost management reflects a broader trend in the industry to adapt to these challenges. The growth in hospice census aligns with the increasing demand for end-of-life care services.

Comparison to Industry Standards

• Enhabit's home health 30-day hospital readmission rate is 23.3% better than the national average, indicating a strong performance in patient care quality compared to industry benchmarks.
• The company's hospice patient visits in the last days of life are 53.2% better than the national average, suggesting a higher level of care and support for hospice patients compared to industry standards.
• While Enhabit's adjusted EBITDA growth is positive, the decline in home health revenue and Medicare admissions is a concern, as many competitors are also facing similar challenges in the home health sector.
• Competitors like LHC Group and Amedisys have also reported mixed results, with some segments showing growth while others face headwinds, indicating that the challenges Enhabit is facing are not unique to the company.

Stakeholder Impact

• Shareholders will be concerned about the net loss and downward revision of guidance.
• Employees may be affected by cost management initiatives and potential restructuring.
• Customers (patients) may benefit from the company's focus on quality care, as indicated by the better-than-average readmission rates and hospice care metrics.
• Suppliers and creditors may be impacted by the company's financial performance and debt reduction efforts.

Next Steps

• The company will host an investor conference call on November 7, 2024, to discuss the third quarter results.
• Enhabit will continue to focus on its payor innovation strategy and cost management initiatives.

Key Dates

Keywords

Enhabit, home health, hospice, EBITDA, Medicare, admissions, revenue, debt reduction, payor innovation, readmission rate